RHHBY - JNJ CEO Signals No Rush Into Weight-Loss Drug Realm Emphasizes Different Priorities | Benzinga
Johnson & Johnson (NYSE: JNJ) has no immediate plans to venture into weight-loss drugs due to the existing competition saturation, as Chief Executive Officer Joaquin Duato highlighted.
During the firm's investor day on Tuesday, Duato emphasized that the company's priorities lie in extensive expansion, particularly within neurology and oncology.
Also Read: Johnson & Johnson's Strategic Forecast: Targets 5%-6% Operational Sales Growth For FY24.
Although dismissing the notion of entering this specific drug category for now, Duato did leave a slight window